The long tail of oncogenic drivers in prostate cancer

Joshua Armenia,Stephanie A. M. Wankowicz,David Liu,Jianjiong Gao,Ritika Kundra,Ed Reznik,Walid K. Chatila,Debyani Chakravarty,G. Celine Han,Ilsa Coleman,Bruce Montgomery,Colin Pritchard,Colm Morrissey,Christopher E. Barbieri,Himisha Beltran,Andrea Sboner,Zafeiris Zafeiriou,Susana Miranda,Craig M. Bielski,Alexander V. Penson,Charlotte Tolonen,Franklin W. Huang,Dan Robinson,Yi Mi Wu,Robert Lonigro,Levi A. Garraway,Francesca Demichelis,Philip W. Kantoff,Mary-Ellen Taplin,Wassim Abida,Barry S. Taylor,Howard I. Scher,Peter S. Nelson,Johann S. de Bono,Mark A. Rubin,Charles L. Sawyers,Arul M. Chinnaiyan,PCF/SU2C International Prostate Cancer Dream Team,Nikolaus Schultz,Eliezer M. Van Allen,

DOI: https://doi.org/10.1038/s41588-018-0078-z

IF: 30.8

2018-04-02

Nature Genetics

Abstract:Comprehensive genomic characterization of prostate cancer has identified recurrent alterations in genes involved in androgen signaling, DNA repair, and PI3K signaling, among others. However, larger and uniform genomic analysis may identify additional recurrently mutated genes at lower frequencies. Here we aggregate and uniformly analyze exome sequencing data from 1,013 prostate cancers. We identify and validate a new class of E26 transformation-specific (ETS)-fusion-negative tumors defined by mutations in epigenetic regulators, as well as alterations in pathways not previously implicated in prostate cancer, such as the spliceosome pathway. We find that the incidence of significantly mutated genes (SMGs) follows a long-tail distribution, with many genes mutated in less than 3% of cases. We identify a total of 97 SMGs, including 70 not previously implicated in prostate cancer, such as the ubiquitin ligase CUL3 and the transcription factor SPEN. Finally, comparing primary and metastatic prostate cancer identifies a set of genomic markers that may inform risk stratification.

genetics & heredity

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to identify new driver genes and pathways in prostate cancer through large - scale and unified genomic analysis. Although previous studies have identified some recurrent gene alterations in prostate cancer, such as genes in androgen signaling, DNA repair, and PI3K signaling pathways, these studies may have failed to discover recurrently mutated genes with lower frequencies due to small sample sizes. The authors hypothesized that performing mutation significance analysis using statistical and biological frameworks in a large and uniformly analyzed whole - exome sequencing (Whole - Exome Sequencing, WES) cohort could identify new genes and pathways, thereby more precisely defining the genomic landscape of prostate cancer.

Specifically, the main objectives of the paper include:
1. **Identify new significantly mutated genes (SMGs)**: Analyze the WES data of 1,013 prostate cancer samples to identify genes that are significantly mutated in prostate cancer and have not been reported before.
2. **Explore new pathways and functional categories**: Integrate focal copy number events and available ETS fusion data, and classify the discovered genes by pathway and function to identify new biologically relevant pathways.
3. **Compare primary and metastatic tumors**: Systematically compare genomic alterations between primary and metastatic prostate cancers to determine genes and pathways associated with disease progression.
4. **Evaluate the clinical significance of genomic markers**: Identify genomic markers that may be used for risk stratification, especially in local prostate cancer.

Through these objectives, the paper aims to expand the understanding of genomic heterogeneity in prostate cancer and provide potential biomarkers and therapeutic targets for future clinical applications.